New Study Uncovers the Dark Side of ATP
Researchers have found that one of the most common and hard-working substances in the body may have a Jekyll and Hyde quality in rosacea patients, assuming a darker role when activated by flare-up triggers.
The following announcement was issued by CollaGenex Pharmaceuticals:
FIRST ORAL DRUG FOR ROSACEA
(doxycycline, USP) capsules 40 mg*
* 30 mg immediate release and 10 mg delayed release beads
The following announcement was issued by the National Women's Health Resource Center:
Do You Live in a Dry Eye Hot Spot?
Trail of Tears May Lead Scientists To First Diagnostic Test for Rosacea
Survey Shows Facial Disorder Hurts More Than Appearance
BARRINGTON, Illinois (February 20, 2006) -- While the often-devastating impact of rosacea on facial appearance is well recognized, a new survey shows that physical discomfort is also experienced by the majority of people with this red-faced, acne-like disorder now estimated to affect more than 14 million Americans.
New Research Grants Awarded to Further Knowledge of Rosacea
BARRINGTON, Illinois (January 11, 2006) -- The National Rosacea Society (NRS) announced that five new studies have been awarded funding as part of its research grants program to advance scientific knowledge of the potential causes and other key aspects of this chronic and potentially devastating disorder that affects an estimated 14 million Americans.